The Board of Directors of Rodin Therapeutics, a Cambridge, MA-based biotechnology company applying insights from epigenetics to develop novel therapeutics for neurological disorders, has appointed Adam J. Rosenberg as Chief Executive Officer.
Mr. Rosenberg brings almost 20 years of entrepreneurial and transactional leadership, and will also be appointed to Rodin’s Board of Directors.
He most recently served as co-founder, director and Chief Executive Officer at Teleos Therapeutics, a biotechnology company leveraging insights in zebrafish chemical biology and novel high throughput screening technologies to discover new treatments for central nervous system disorders.
Mr. Rosenberg also co-founded and served on the Board of Directors of Clean Membranes, a materials company based on MIT technology, and since 2009 has advised or served in interim executive roles with numerous companies in the healthcare and biotechnology sectors.
From 2005 to 2009, he co-founded and served as CEO of Link Medicine Corporation, a company focused on developing novel disease-modifying neurodegenerative treatments.
Bruce Booth, Partner at Atlas Venture and Chairman of Rodin’s Board of Directors, served as Rodin’s acting CEO until Mr. Rosenberg’s hiring.
Co-founded in 2013 by Atlas Venture and Proteros Biostructures, Rodin Therapeutics is discovering and developing therapeutics for cognitive disorders, applying insights into the role of epigenetics and structural biology capabilities.
The company closed a $12.9m Series A financing round in May 2014.